Navigation Links
Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
Date:5/4/2009

POT-4 well tolerated by all subjects and sustained levels of drug reported after one treatment

LOUISVILLE, Ky., May 4 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it successfully completed its Phase I ASaP (Assessment of Safety of Intravitreal POT-4 Therapy for Patients with Neovascular Age-Related Macular Degeneration) clinical trial for the company's leading drug candidate, POT-4.

The ASaP trial was an open label, first-in-man, multi-center, single escalating dose study. The primary safety endpoint of this trial was achieved and the drug was well tolerated by all subjects at all doses tested, based on clinical signs, ophthalmic examinations, and laboratory results. No drug-related serious adverse events and no identifiable intraocular inflammation were reported. Additionally, significant sustained levels of POT-4 were consistently measured via serum analysis in subjects receiving the highest dose studied. The current POT-4 formulation is expected to provide sustained therapeutic ocular levels of the drug for several months following a single injection.

The data accumulated so far support the implementation of a comprehensive Phase II clinical program to further define the safety, efficacy and pharmacokinetic profile of POT-4 as a treatment for both dry and wet AMD.

"The safety and pharmacokinetic data strongly support the further development of POT-4 as a first-in-class treatment for patients with AMD," said Cedric Francois, President and CEO of Potentia Pharmaceuticals. "We believe that POT-4 has significant promise based on these early-stage findings and look forward to further testing of POT-4 in this disease, which is so prevalent and devastating to those affected by it."

About POT-4

POT-4 is a complement factor C3
'/>"/>

SOURCE Potentia Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
2. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
3. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
4. Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
5. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
6. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
7. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
8. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
9. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
10. Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
11. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LAKE FOREST, Ill. , Dec. 19, 2014 /PRNewswire/ ... the world,s leading provider of injectable drugs and infusion ... the J.P. Morgan 33rd Annual Healthcare Conference on Wednesday, ... The presentation is scheduled to begin at 10:30 ... will be available to all interested parties through a ...
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... 18, 2014  Sage Analytics ( www.sageanalytics.com ), ... for the testing of marijuana potency and moisture ... Luminary™ Profiler, the industry,s first product suite capable ... cost-effective, portable unit. Designed from the ... the cannabis industry, the Luminary™ Profiler utilizes specially ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
(Date:12/22/2014)... Explorys, the leader in big data-driven ... team: Greg Yarrington as Vice President of Operations, Adam ... as Vice President of Solutions. These new leaders are ... in 2015 to support client demand for the company’s ... and growth of its partner network. , Since ...
(Date:12/22/2014)... 22, 2014 Pasadena sleep apnea ... for sleep apnea. Drowsy drivers are 15 times more ... are well-rested, and some experts believe that sleep-deprived drivers ... intoxicated drivers. Unfortunately, millions of Americans may be sleep-deprived ... of Sleep Medicine, about 18 million Americans have sleep ...
(Date:12/22/2014)... Christmas is days away, and last minute ... easy solution that will please: the Sublime Gift Card ... from $25 up to $350," says Kathy Heshelow, founder of ... a wide array of skin care products and Skin Brushes." ... dates. , Gift delivery past shipping deadlines, or those ...
(Date:12/22/2014)... At the annual National ... in San Antonio, esteemed experts and thought leaders ... stand in the way of successful organizational performance: ... premier faculty development opportunity is made possible through ... is to assist nurse educators to advance to ...
(Date:12/21/2014)... offers a wide range of women’s dresses, fashionable accessories ... BellasDress Christmas Sale , offering big discounts on all ... a famous online supplier of women’s dresses; it always ... promotions. The dress experts of the company provide professional ... of offering high quality wedding dresses and women’s special ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... 30 Thoratec,Corporation (Nasdaq: THOR ), a ... today that the FDA Circulatory System Devices,Advisory Panel ... the company,s PMA (PreMarket Approval) allowing the use ... as a,bridge-to-transplantation (BTT)., The HeartMate II is ...
... Families with Deployed Service Members ... ... to Operation Cares, which supports the needs of the,more than 4,000 of South ... the central market area at,TriWest, will present the check to Steve Doohen, secretary ...
... cell agency is inviting for-profit companies to apply ... for Taxpayer and Consumer Rights,(FTCR) noted today and ... the awards process to prevent abuse., The ... calls for applications for two types of grants. ...
... following is a,statement from Henrietta H. Fore, USAID ... again recognizes World AIDS,Day and the more than ... Through the President,s Emergency Plan for AIDS Relief ... supporting those,battling the disease, as well as those ...
... ALEXANDRIA, Va., Nov. 30 The Pharmaceutical,Care ... falsely claiming,that pending legislation requiring prompt payment ... cost billions of dollars. PCMA represents 10,pharmacy ... administer,prescription drug plans. In response, Bruce Roberts, ...
... Neurochem Inc. (NASDAQ:,NRMX; TSX: NRM) today announces the ... Business. Dr. Calais joined Neurochem,in 2003, and is ... "Dr. Calais has made a significant contribution ... and we,are grateful for having had the benefit ...
Cached Medicine News:Health News:Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation 2Health News:Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation 3Health News:TriWest Contributes $10,000 to Operation Cares for South Dakota's Military Families 2Health News:Close Scrutiny Needed as First Stem Cell Grants Offered to For-Profit Companies, Consumers Say 2Health News:On World AIDS Day, Keeping the Promise to Stop AIDS Through the Power of Partnerships 2Health News:NCPA Statement on Bogus PCMA Study About Cost to Fix Medicare Part D 2Health News:Neurochem announces departure of Dr. Philippe Calais, President, Global Business 2
This flexiable metal clip-on easily attaches to most frames and allows for excellent radiation protection. Not available with side shields or in prescription....
All New Ultra Pb Series Glasses...
... eye protection Properly manufactured radiation protective ... radiation. Our high quality frames and materials ... minimized weight. Our lenses are made of ... all industry standards. Most Pulse Glasses are ...
... Stylish and comfortable eye protection ... approximately 90% of scatter radiation. Our high ... protection and comfort with minimized weight. Our ... leaded) optics that meet all industry standards. ...
Medicine Products: